Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Camda 2018 @ismb

    Dear Colleagues,

    The Call for Contributions to CAMDA is now open!

    CAMDA is a full conference track at ISMB (www.camda.info).

    Researchers world-wide take the CAMDA Challenge (contest.camda.info) - compete with the best in an open-ended data analysis contest!

    Your choice of challenges 2018:
    * The MetaSUB Forensics Challenge presents hundreds of novel city microbiome profiles. Construct urban microbiome fingerprints and identify the geographical origin of mystery samples.
    * The CMap Drug Safety Challenge presents clinical toxicity results and gene expression responses to hundreds of drugs. Compare or integrate responses of multiple cell lines, predict drug induced liver injury in humans. Opt into an FDA meta-analysis.
    * The Cancer Data Integration Challenge presents clinical data, RNA-seq and microarray gene expression, and CNV from aCGH. Demonstrate a robust analysis approach improving the state of the art for both Breast Cancer and Neuroblastoma.

    Join us for a stimulating scientific meeting and lively discussions in Chicago 07-08 July 2018!

    Follow us on twitter @CAMDA_conf


    See you in Chicago!

    For the organizing committee,
    Joaquin Dopazo, Seville, Spain
    Diane Kovats, U.S.A.
    David Kreil, Vienna, Austria
    Paweł Łabaj, Kraków, Poland
    Weida Tong, Little Rock, U.S.A.
    Wenzhong Xiao, Stanford/Boston, U.S.A.


    Background:

    CAMDA was founded in 2000 (Nature 411, 885. Nature 424, 610) to provide a forum for the critical assessment of different techniques used in large-scale data analysis in the life-sciences, including but not limited to high-dimensional gene expression profiling. It aims to establish the state-of-the-art in analysis methods for Big Data in the Life Sciences, as well as identify progress and highlight promising directions for future efforts. To this end, CAMDA adopted the approach of a community-wide contest, with the scientific community analysing the same data sets. Researchers worldwide are invited to take the CAMDA challenge, which has become a prominent fixture (cf. Nature Methods 5, 569).

    Selected contributions are presented though talks and posters. Results and methods of the different analyses are discussed and compared at the conference, with delegates voting for the best presentations. Extended papers are published in a special issue of Biology Direct (fully indexed and open access). Methods papers are eligible for the regular ISMB proceedings track in Bioinformatics.

    Keynotes by leading researchers in the field provide further focus points for discussion at the meeting, and have recently included talks by Atul Butte and Sandrine Dudoit (Stanford), Mark Gerstein (Yale), Curtis Huttenhower (Harvard), John Quackenbush (Dana Farber Cancer Institute, Boston), Chris Sander (Memorial Sloan Kettering Cancer Center, New York), Eran Segal (Weizmann Institute, Israel), John Storey and Olga Troyanskaya (Princeton), and Terry Speed (Berkeley & WEHI).
    Pawel Labaj

  • #2
    MetaSUB Forensics Challenge

    MetaSUB Forensics Challenge

    The MetaSUB International Consortium is building a longitudinal metagenomic map of mass-transit systems and other public spaces across the globe. The consortium maintains a strategic partnership with CAMDA and this year provides data from global City Sampling Days for the first-ever multi-city forensic analyses.

    CAMDA delegates receive access to hundreds of novel MetaSUB samples, comprising several gigabases of whole genome shotgun (WGS) metagenomics data. Samples are collected from multiple surfaces in mass-transit systems (handrails, ticket machines screens and keypads, plastic, metal, or wooden benches, etc.). The primary data set covers multiple cities around the world, with tens of samples per city. Together, they form a unique resource for the study of biodiversity within and across geographic locations or surface types.

    Three complementary independent test sets will be provided for exploration:
    • About 30 new samples from different cities and surface types already featured in the primary dataset - can you tell which?
    • At least 3 different new 'mystery' cities not featured before. Each new city will be represented by 10 or more samples.
    • 20-30 samples from new 'mystery' locations not featured before, with no information about which samples might come from the same city.


    Analysis suggestions:
    A key challenge in genomic forensics is the construction of a microbiome fingerprint which will allow the identification of the geographical origin of a sample.

    Typical considerations include:
    • How and how well can we exploit metagenomic fingerprints for identifying the origin of a sample?
    • How reliably can we identify single samples?
    • How do multiple samples and/or multiple surface types affect the quality of our predictions?


    Join us for a stimulating scientific meeting and lively discussions in Chicago 07-08 July 2018!

    Follow us on twitter @CAMDA_conf
    Pawel Labaj

    Comment


    • #3
      MetaSUB Forensics Challenge

      MetaSUB Forensics Challenge

      The MetaSUB International Consortium is building a longitudinal metagenomic map of mass-transit systems and other public spaces across the globe. The consortium maintains a strategic partnership with CAMDA and this year provides data from global City Sampling Days for the first-ever multi-city forensic analyses.

      CAMDA delegates receive access to hundreds of novel MetaSUB samples, comprising several gigabases of whole genome shotgun (WGS) metagenomics data. Samples are collected from multiple surfaces in mass-transit systems (handrails, ticket machines screens and keypads, plastic, metal, or wooden benches, etc.). The primary data set covers multiple cities around the world, with tens of samples per city. Together, they form a unique resource for the study of biodiversity within and across geographic locations or surface types.

      Three complementary independent test sets will be provided for exploration:
      • About 30 new samples from different cities and surface types already featured in the primary dataset - can you tell which?
      • At least 3 different new 'mystery' cities not featured before. Each new city will be represented by 10 or more samples.
      • 20-30 samples from new 'mystery' locations not featured before, with no information about which samples might come from the same city.


      Analysis suggestions:
      A key challenge in genomic forensics is the construction of a microbiome fingerprint which will allow the identification of the geographical origin of a sample.

      Typical considerations include:
      • How and how well can we exploit metagenomic fingerprints for identifying the origin of a sample?
      • How reliably can we identify single samples?
      • How do multiple samples and/or multiple surface types affect the quality of our predictions?


      Join us for a stimulating scientific meeting and lively discussions in Chicago 07-08 July 2018!

      Follow us on twitter @CAMDA_conf
      Pawel Labaj

      Comment


      • #4
        CMap Drug Safety Challenge

        CMap Drug Safety Challenge

        Attrition in drug discovery and development due to safety / toxicity issues remains a significant concern, and there are strong efforts to identify and mitigate risk as early as possible. Drug-induced liver injury (DILI) is one of the primary problems in drug development and regulatory clearance due to the poor performance of existing preclinical models. There is a pressing need to evaluate alternative methods for predicting DILI, with great hopes being placed in modern approaches from statistics and machine learning applied to genome scale profiling data. A critical question thus is if we can better integrate, understand, and exploit information from cell-based screens like the Broad Institute Connectivity Map (CMap, Science 313, Nature Reviews Cancer 7).

        This CAMDA challenge focuses on understanding or predicting drug induced liver injury in humans from cell-based screens, specifically the CMap gene expression responses of two different cancer cell lines (MCF7 and PC3) to 276 drug compounds. To also support supervised approaches, we provide clinical DILI results as training labels for 190 drugs.

        Analysis suggestions:
        • Identification and interpretation of differences in cell-line response across drugs and across cell-line type
        • Prediction of human clinical DILI results from cell-line responses


        Everyone will be invited to publish their method and results as a full research paper in the CAMDA Proceedings after the conference. This year, however, in addition to the regular open-ended data analysis contest, we can also offer all participants to contribute to an FDA meta-analysis paper of prediction methods that will be published separately. If you chose to take part in this additional track, you need to freeze your solution by 15 April and submit a short description of approach, training performance (accuracy, specificity, sensitivity, MCC, …) and your DILI predictions for the 86 unlabeled drugs. The labels for these 86 drugs will be released 16 April, giving you about four weeks to finalize an extended abstract for submission to CAMDA.

        Join us for a stimulating scientific meeting and lively discussions in Chicago 07-08 July 2018!

        Follow us on twitter @CAMDA_conf
        camda.info
        Pawel Labaj

        Comment


        • #5
          CMap Drug Safety Challenge

          CMap Drug Safety Challenge

          Attrition in drug discovery and development due to safety / toxicity issues remains a significant concern, and there are strong efforts to identify and mitigate risk as early as possible. Drug-induced liver injury (DILI) is one of the primary problems in drug development and regulatory clearance due to the poor performance of existing preclinical models. There is a pressing need to evaluate alternative methods for predicting DILI, with great hopes being placed in modern approaches from statistics and machine learning applied to genome scale profiling data. A critical question thus is if we can better integrate, understand, and exploit information from cell-based screens like the Broad Institute Connectivity Map (CMap, Science 313, Nature Reviews Cancer 7).

          This CAMDA challenge focuses on understanding or predicting drug induced liver injury in humans from cell-based screens, specifically the CMap gene expression responses of two different cancer cell lines (MCF7 and PC3) to 276 drug compounds. To also support supervised approaches, we provide clinical DILI results as training labels for 190 drugs.

          Analysis suggestions:
          • Identification and interpretation of differences in cell-line response across drugs and across cell-line type
          • Prediction of human clinical DILI results from cell-line responses


          Everyone will be invited to publish their method and results as a full research paper in the CAMDA Proceedings after the conference. This year, however, in addition to the regular open-ended data analysis contest, we can also offer all participants to contribute to an FDA meta-analysis paper of prediction methods that will be published separately. If you chose to take part in this additional track, you need to freeze your solution by 15 April and submit a short description of approach, training performance (accuracy, specificity, sensitivity, MCC, …) and your DILI predictions for the 86 unlabeled drugs. The labels for these 86 drugs will be released 16 April, giving you about four weeks to finalize an extended abstract for submission to CAMDA.

          Join us for a stimulating scientific meeting and lively discussions in Chicago 07-08 July 2018!

          Follow us on twitter @CAMDA_conf

          camda.conf
          Pawel Labaj

          Comment


          • #6
            REMINDER !!!!

            To present late breaking methods research or analyses of the CAMDA challenge data sets you need to register a 200-word abstract as intention to submit by 5 April, specifying CAMDA as intended target audience.
            ISCB - International Society for Computational Biology
            Pawel Labaj

            Comment


            • #7
              Keynote speakers

              We are delighted to confirm Lawrence Lesko (University of Florida, U.S.A.) and Daniel Huson (University of Tübingen, Germany) as leading keynote speakers at CAMDA2018!

              Join us for a stimulating scientific meeting and lively discussions in Chicago 07-08 July 2018!

              CAMDA,CAMDA 2024,Critical Assessment of Massive Data Analysis,Critical Assessment of Microarray Data Analysis,ISMB,ECCB,MGED,FGED,FDA,SEQC,ONT,BERT,neuroblastoma,MetaSUB,metagenomics,oxford nanopore,cancer,breast cancer,metabric,data integration,toxicogenomics,TGx,DILI,personalized medicine,precision medicin,drugs,TCGA,GDC,2024


              Follow us on twitter @CAMDA_conf
              Pawel Labaj

              Comment


              • #8
                Early bird discount

                Early bird discount ends 7 June!

                Check out our agenda + select CAMDA during registration

                See you for an exciting conference in Chicago!
                Pawel Labaj

                Comment

                Latest Articles

                Collapse

                • seqadmin
                  Techniques and Challenges in Conservation Genomics
                  by seqadmin



                  The field of conservation genomics centers on applying genomics technologies in support of conservation efforts and the preservation of biodiversity. This article features interviews with two researchers who showcase their innovative work and highlight the current state and future of conservation genomics.

                  Avian Conservation
                  Matthew DeSaix, a recent doctoral graduate from Kristen Ruegg’s lab at The University of Colorado, shared that most of his research...
                  03-08-2024, 10:41 AM
                • seqadmin
                  The Impact of AI in Genomic Medicine
                  by seqadmin



                  Artificial intelligence (AI) has evolved from a futuristic vision to a mainstream technology, highlighted by the introduction of tools like OpenAI's ChatGPT and Google's Gemini. In recent years, AI has become increasingly integrated into the field of genomics. This integration has enabled new scientific discoveries while simultaneously raising important ethical questions1. Interviews with two researchers at the center of this intersection provide insightful perspectives into...
                  02-26-2024, 02:07 PM

                ad_right_rmr

                Collapse

                News

                Collapse

                Topics Statistics Last Post
                Started by seqadmin, 03-14-2024, 06:13 AM
                0 responses
                33 views
                0 likes
                Last Post seqadmin  
                Started by seqadmin, 03-08-2024, 08:03 AM
                0 responses
                72 views
                0 likes
                Last Post seqadmin  
                Started by seqadmin, 03-07-2024, 08:13 AM
                0 responses
                81 views
                0 likes
                Last Post seqadmin  
                Started by seqadmin, 03-06-2024, 09:51 AM
                0 responses
                68 views
                0 likes
                Last Post seqadmin  
                Working...
                X